23 Aug 2016 15:01
For immediate release | 23 August 2016 |
ABCAM PLC
("Abcam" or "the Company")
BLOCK LISTING SIX MONTHLY RETURN
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
Name of applicant: | Abcam plc | |||
Name of scheme: | 1. Abcam 2005 Share Option Scheme 2. Abcam Share Incentive Plan 3. Abcam Company Share Option Plan 4. Abcam Long Term Incentive Plan 5. Annual Bonus Plan | |||
Period of return: | From: | 6 February 2016 | To: | 7 August 2016 |
Balance of unallotted securities under scheme(s) from previous return: | 1. 2,399,998 2. 189,772 3. 558,790 4. 1,874,233 5. 387,958 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 1. - 2. - 3. - 4. - 5. - | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 1. 192,663 2. - 3. 63,958 4. 23,455 5. 7,139 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1. 2,207,335 2. 189,772 3. 494,832 4. 1,850,778 5. 380,819 | |||
Name of contact: | Suzanne Smith, Company Secretary |
Telephone number of contact: | + 44 (0) 1223 696 000 |
For further information, please contact:
Abcam | |
Suzanne Smith, Company Secretary
| + 44 (0) 1223 696 000 |
J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker | |
James Mitford / Christopher Cargill | + 44 (0) 20 7742 4000 |
Notes to Editors
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Abcam's ten offices are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and www.abcamplc.com